Vimarsana
Biggest News Aggregation in the World

Page 17 - Heca News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Heca. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Heca Today - Breaking & Trending Today

What is aspartame and what do the new WHO rulings mean? - Vimarsana News

What is aspartame and what do the new WHO rulings mean?

Aspartame, a popular artificial sweetener found in Diet Coke, chewing gum, yoghurt and other food products, is a "possible carcinogen" but it remains safe to consume at the existing daily intake guidelines, according to new rulings from two different World Health Organization-linked groups.

Insight: The meds they bought were toxic. Now Gambian parents seek justice - Vimarsana News

Insight: The meds they bought were toxic. Now Gambian parents seek justice

Families of 20 Gambian children who died after consuming cough syrups made in India will take their government to court this month for allegedly mishandling drug imports – a rare step in one of Africa's poorest countries, where few have the means to challenge authorities.

Exclusive: Delays getting higher dose Wegovy to patients reported by US doctors - Vimarsana News

Exclusive: Delays getting higher dose Wegovy to patients reported by US doctors

Some U.S. patients taking the two highest doses of Novo Nordisk's Wegovy weight-loss drug are facing difficulty filling their prescriptions, eight doctors around the country told Reuters this week, suggesting a new supply challenge for the popular medicine.

Exclusive: MoonLake Immunotherapeutics explores sale-sources - Vimarsana News

Exclusive: MoonLake Immunotherapeutics explores sale-sources

MoonLake Immunotherapeutics , a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter.

U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 mln - Vimarsana News

U.S. watchdog lifts price estimate for Bluebird, Vertex/CRISPR gene therapies to $2.1 mln

An influential U.S. drug pricing watchdog raised the price estimate of two experimental gene therapies from Vertex Pharmaceuticals /CRISPR Therapeutics and bluebird bio to as much as $2.05 mln, saying the new price can be cost effective to treat sickle cell disease.